Dr Frank Mathias, CEO of Rentschler Biopharma said: “I am delighted to welcome Günter, Christiane, and Elke to Rentschler Biopharma”
Rentschler Biopharma, a global CDMO for biopharmaceuticals, has strengthened its leadership team with the hiring of several senior level, highly experienced biopharmaceutical executives.
Dr Günter Stempfer joined the Company on January 1, 2022, as Head of Global Strategic Development. He previously supported Rentschler Biopharma in an operations consulting capacity. In this recently created role, Stempfer will work with the team to drive strategic initiatives and projects across the company’s sites. He brings more than 25 years of experience in the biopharmaceutical industry, having held various leadership positions.
Christiane Bardroff has joined Rentschler as Senior VP Client Program Management, effective February 1, 2022. From previous positions at Teva Biotech and Roche Penzberg, Bardroff brings experience in the organisation of complex projects. She will add to the company’s existing client program management (CPM) function.
Elke Ottenschläger joined February 1, 2022, as Senior VP Clinical and Commercial Manufacturing. She joined from Lonza, where she was Head Global Technical Functions and Head Global Tech Transfer, and will lead the company’s production teams, focusing on implementing a growth strategy at the Laupheim site.
Dr Christian Hunzinger, who initiated the company’s CPM unit, has transitioned to the recently created position of VP Analytical Science, effective February 1, 2022. The role is hoped to enable the company to respond to the increasing client need for advanced in-process analytics for data-based development.
Dr Frank Mathias, CEO of Rentschler Biopharma said: “I am delighted to welcome Günter, Christiane, and Elke to Rentschler Biopharma. Each brings great expertise and knowledge that will further strengthen our client experience. I am also pleased that Christian will take on his important new role at the interface between process science and quality control. The additions and changes announced today are important as we help our clients to bring life-saving medicines to patients with serious or rare diseases.”